Investigating and evaluating potential antigen binding sites for monoclonal anti-HER2 antibodies: The LightDock approach.

ABSTRACT: Monoclonal antibodies targeting HER2, a receptor overexpressed in certain cancer cells, have greatly improved the treatment of HER2-positive cancers. In addition, anti-HER2 antibodies play a critical role in diagnostic applications, enabling accurate detection of HER2 expression levels. Advancing antibody-based therapies and diagnostic tools require a thorough understanding of binding interactions, but it remains challenging due to complex antibody protein structure and its flexibility, particularly within their complementarity-determining regions. In this study we utilized LightDock, a molecular docking tool simulating protein-protein interactions which can incorporate flexibility that allows the in silico analysis of flexible proteins like antibody. Using LightDock we investigated

SUBMITTER: Stefanczyk E 

PROVIDER: S-EPMC12182776 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature